NEW YORK (360Dx) — HalioDx today announced that Gencell Pharma will market and distribute the Immunoscore Colon assay in Colombia.

HalioDx's test predicts the risk of recurrence in patients with early-stage colon cancer and guides oncologists in decisions about therapies for stage II and III colon cancers. Combining tissue diagnostic and advanced image analysis technologies, Immunoscore Colon quantifies T-cells which have penetrated into the core of the colon core and its invasive margin.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.